SWOG clinical trial number
SWOG-8955
Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II
Closed
Phase
Accrual
58%
Published
Abbreviated Title
Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II
Activated
06/15/1992
Closed
11/01/1993
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1996
Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and roferon-A: A Southwest Oncology Group study.
1994
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report.
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase